COSCIENS Biopharma Statistics
Total Valuation
CSCI has a market cap or net worth of $8.52 million. The enterprise value is -$8.76 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CSCI has 3.12 million shares outstanding. The number of shares has increased by 6.18% in one year.
| Current Share Class | 3.12M |
| Shares Outstanding | 3.12M |
| Shares Change (YoY) | +6.18% |
| Shares Change (QoQ) | +39.91% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.46, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.46 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,624.50 |
Financial Efficiency
Return on equity (ROE) is -100.27% and return on invested capital (ROIC) is -56.49%.
| Return on Equity (ROE) | -100.27% |
| Return on Assets (ROA) | -31.52% |
| Return on Capital (ROIC) | -56.49% |
| Revenue Per Employee | $402,833 |
| Profits Per Employee | -$1.93M |
| Employee Count | 12 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0.39 |
Taxes
| Income Tax | -473,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 2.27 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 3.25 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 31.84 |
| Average Volume (20 Days) | 4,100 |
Short Selling Information
The latest short interest is 2,213, so 0.07% of the outstanding shares have been sold short.
| Short Interest | 2,213 |
| Short Previous Month | 1,339 |
| Short % of Shares Out | 0.07% |
| Short % of Float | 0.08% |
| Short Ratio (days to cover) | 1.64 |
Income Statement
In the last 12 months, CSCI had revenue of $4.83 million and -$23.21 million in losses. Loss per share was -$14.28.
| Revenue | 4.83M |
| Gross Profit | 4.17M |
| Operating Income | -21.75M |
| Pretax Income | -18.05M |
| Net Income | -23.21M |
| EBITDA | -21.60M |
| EBIT | -21.75M |
| Loss Per Share | -$14.28 |
Full Income StatementBalance Sheet
The company has $20.00 million in cash and $1.62 million in debt, giving a net cash position of $18.38 million or $5.89 per share.
| Cash & Cash Equivalents | 20.00M |
| Total Debt | 1.62M |
| Net Cash | 18.38M |
| Net Cash Per Share | $5.89 |
| Equity (Book Value) | 20.01M |
| Book Value Per Share | 6.41 |
| Working Capital | 20.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$27.19 million and capital expenditures -$736,000, giving a free cash flow of -$27.93 million.
| Operating Cash Flow | -27.19M |
| Capital Expenditures | -736,000 |
| Free Cash Flow | -27.93M |
| FCF Per Share | -$8.94 |
Full Cash Flow StatementMargins
| Gross Margin | 86.18% |
| Operating Margin | -449.88% |
| Pretax Margin | -489.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |